ESPR LIST stock news:
Lipid Sciences Inc. Announces Jan Johansson, M.D., Ph.D. Joins as VP of
Clinical Research and Development
PLEASANTON, Calif., Nov 19, 2001 (BW HealthWire) -- Lipid Sciences Inc. today
announced that Jan Johansson, M.D., Ph.D. has joined as Vice President of
Clinical Research and Development.
Dr. Johansson joins Lipid Sciences from Esperion Therapeutics, a company he
co-founded. At Esperion, Dr. Johansson served as VP of Clinical Affairs and Sr.
Clinical Research Fellow, being responsible for five clinical/development
projects in the area of reverse cholesterol transport.
Prior to Esperion, Dr. Johansson was at Pharmacia (Stockholm) heading the
atherosclerosis development group. Dr. Johansson, M.D., Ph.D., and Associate
Professor of the Karolinska Institute (Sweden) also brings 16 years experience
as a physician and scientific physician.
Dr. Phil Radlick, CEO and President of Lipid Sciences Inc. commented on Dr.
Johansson's appointment by saying: "Reverse cholesterol transport is a new area
of medicine and few people have clinical experience in this field. We are very
fortunate to have the experience of Dr. Johansson to lead our clinical effort,
which we expect will begin shortly."
Dr. Johansson commented on joining Lipid Sciences Inc. by saying: "It is
exciting to be part of a team working to commercialize the Vascular Lipid
Removal technology platform. The technology system has the potential to acutely
and significantly remove cholesterol deposits within blood vessels thereby
reversing atherosclerosis and cardiovascular diseases. In addition, there are
several other applications of plasma delipidation, patented by Lipid Sciences,
that can be used to address unmet medical needs."
As previously announced on July 10, 2001, NZ Corp. (AMEX:NZ) and Lipid Sciences
Inc. have executed a definitive merger agreement.
Lipid Sciences is a medical technology company with a patented technology that
has been shown in animal models to be capable of reversing atherosclerotic
plaques. The technology has also been shown to inactivate lipid-enveloped
viruses.
Lipid-enveloped viruses that may be treatable by the technology include HIV, and
Hepatitis B and C. Lipid Sciences expects to begin clinical safety trials in
humans during the first quarter of 2002.
NZ is a real estate investor and owner, and short-term commercial real estate
lender. Through its wholly-owned subsidiary, Bridge Financial Corp., NZ acts as
a direct lender in providing time sensitive, short-term real estate loans in the
southwestern states and California.
As explained in previous press releases NZ has been actively evaluating its
assets as part of its corporate strategy to explore other opportunities.
This press release contains "forward-looking statements" as defined in the
Private Securities Litigation Reform Act of 1995. These statements are based on
current expectations, forecasts and assumptions that are subject to risks and
uncertainties which could cause actual outcomes and results to differ materially
from these statements. A further list and description of risks, uncertainties
and other factors can be found in NZ's filings with the Securities and Exchange
Commission, including the most recently filed Form 10K and Form S-4. Copies of
the Form 10K or Form S-4 are available on request from NZ. The companies
disclaim any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.
NZ filed a definitive joint proxy statement/prospectus on Form S-4 on Nov. 9,
2001, and other documents regarding the proposed merger described in this press
release with the Securities and Exchange Commission. Investors and security
holders are urged to read the definitive joint proxy statement/prospectus
because it contains important information about NZ and Lipid Sciences, and the
proposed merger. A definitive joint proxy statement/prospectus will be mailed to
security holders of NZ and Lipid Sciences seeking their approval of the proposed
merger. Investors and security holders may obtain a free copy of the definitive
joint proxy statement/prospectus and other documents filed by NZ with the SEC at
the SEC's Web site at sec.gov or from NZ by contacting NZ Corp.,
Attn: Corporate Secretary, 333 N. 44th Street, Suite 420, Phoenix, AZ, 85008; or
from Lipid by contacting Lipid Sciences Inc., Attn: Corporate Secretary, 7068
Koll Center Parkway, Suite 401, Pleasanton, CA, 94566. NZ and Lipid Sciences,
and their respective directors and executive officers, as well as MDB Capital
Group LLC may be deemed to be participants in the solicitation of proxies in
favor of the proposed merger and related matters. Information concerning the
directors and executive officers of NZ, Lipid Sciences, and MDB Capital Group
LLC, and their respective beneficial interests may be found in the definitive
joint proxy statement/prospectus filed with the SEC by NZ on Nov. 9, 2001.
CONTACT: Lipid Sciences Inc., Pleasanton
Barry D. Michaels, 925/249-4000
www.lipidsciences.com
or
Lippert/Heilshorn & Associates Inc.
Bruce Voss, 310/691-7100
bvoss@lhai.com
www.lhai.com
URL: businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2001 Business Wire. All rights reserved.
-0-
KEYWORD: CALIFORNIA ARIZONA SWEDEN INTERNATIONAL EUROPE
INDUSTRY KEYWORD: BIOTECHNOLOGY
MEDICAL
REAL
ESTATE
MANAGEMENT
CHANGES
SOURCE:
Lipid
Sciences
Inc.
*** end of story *** |
